Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vabomere in children with complicated urinary tract infection or acute pyelonephritis
2024-516360-29-00Phase 2Authorised
- Sponsor
- Rempex Pharmaceuticals
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of vaborbactam in complicated urinary tract infection (cUTI) and acute pyelonephritis, sponsored by Rempex Pharmaceuticals. Primary endpoint: Safety and tolerability. Planned start Mar 2025; status: authorised.
02
Drugs
vaborbactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on 2024-516360-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516360-29-00.